BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32457458)

  • 1. SIRT3 and GCN5L regulation of NADP+- and NADPH-driven reactions of mitochondrial isocitrate dehydrogenase IDH2.
    Smolková K; Špačková J; Gotvaldová K; Dvořák A; Křenková A; Hubálek M; Holendová B; Vítek L; Ježek P
    Sci Rep; 2020 May; 10(1):8677. PubMed ID: 32457458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status.
    Yu W; Dittenhafer-Reed KE; Denu JM
    J Biol Chem; 2012 Apr; 287(17):14078-86. PubMed ID: 22416140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertrophic preconditioning attenuates myocardial ischemia/reperfusion injury through the deacetylation of isocitrate dehydrogenase 2.
    Ma L; Shi H; Li Y; Gao W; Guo J; Zhu J; Dong Z; Sun A; Zou Y; Ge J
    Sci Bull (Beijing); 2021 Oct; 66(20):2099-2114. PubMed ID: 36654268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertrophic preconditioning attenuates post-myocardial infarction injury through deacetylation of isocitrate dehydrogenase 2.
    Ma LL; Kong FJ; Ma YJ; Guo JJ; Wang SJ; Dong Z; Sun AJ; Zou YZ; Ge JB
    Acta Pharmacol Sin; 2021 Dec; 42(12):2004-2015. PubMed ID: 34163022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Sirt3 inhibits lipid accumulation in macrophages through mitochondrial IDH2 deacetylation.
    Sheng S; Kang Y; Guo Y; Pu Q; Cai M; Tu Z
    Int J Clin Exp Pathol; 2015; 8(8):9196-201. PubMed ID: 26464666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
    Lemonnier F; Cairns RA; Inoue S; Li WY; Dupuy A; Broutin S; Martin N; Fataccioli V; Pelletier R; Wakeham A; Snow BE; de Leval L; Pujals A; Haioun C; Paci A; Tobin ER; Narayanaswamy R; Yen K; Jin S; Gaulard P; Mak TW
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15084-15089. PubMed ID: 27956631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIRT3-Mediated Dimerization of IDH2 Directs Cancer Cell Metabolism and Tumor Growth.
    Zou X; Zhu Y; Park SH; Liu G; O'Brien J; Jiang H; Gius D
    Cancer Res; 2017 Aug; 77(15):3990-3999. PubMed ID: 28536275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
    Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
    Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
    Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
    Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells.
    Matsunaga H; Futakuchi-Tsuchida A; Takahashi M; Ishikawa T; Tsuji M; Ando O
    Biochem Biophys Res Commun; 2012 Jul; 423(3):553-6. PubMed ID: 22683334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
    Akbay EA; Moslehi J; Christensen CL; Saha S; Tchaicha JH; Ramkissoon SH; Stewart KM; Carretero J; Kikuchi E; Zhang H; Cohoon TJ; Murray S; Liu W; Uno K; Fisch S; Jones K; Gurumurthy S; Gliser C; Choe S; Keenan M; Son J; Stanley I; Losman JA; Padera R; Bronson RT; Asara JM; Abdel-Wahab O; Amrein PC; Fathi AT; Danial NN; Kimmelman AC; Kung AL; Ligon KL; Yen KE; Kaelin WG; Bardeesy N; Wong KK
    Genes Dev; 2014 Mar; 28(5):479-90. PubMed ID: 24589777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies.
    Yu W; Denu RA; Krautkramer KA; Grindle KM; Yang DT; Asimakopoulos F; Hematti P; Denu JM
    J Biol Chem; 2016 Feb; 291(7):3268-79. PubMed ID: 26631723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Hydroxyglutarate in Cancer Cells.
    Ježek P
    Antioxid Redox Signal; 2020 Nov; 33(13):903-926. PubMed ID: 31847543
    [No Abstract]   [Full Text] [Related]  

  • 19. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.
    Leonardi R; Subramanian C; Jackowski S; Rock CO
    J Biol Chem; 2012 Apr; 287(18):14615-20. PubMed ID: 22442146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.